In the BioHarmony Drug Report Database

"Preview" Icon

Eptinezumab

Vyepti (eptinezumab) is an antibody pharmaceutical. Eptinezumab was first approved as Vyepti on 2020-02-21. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1 and calcitonin gene-related peptide 2.

 

Trade Name

 

Vyepti
 

Common Name

 

eptinezumab
 

ChEMBL ID

 

CHEMBL3833320
 

Indication

 

 

Drug Class

 

Monoclonal antibodies: humanized, neural indications

Image (chem structure or protein)

Eptinezumab structure rendering